Suppression of experimental autoimmune encephalomyelitis (EAE) by intraperitoneal administration of soluble myelin antigens in Wistar rats

Rivero, Virginia; Maccioni, Mariana; Bucher, A.E.; Roth, German A.; Riera, Clelia M.

doi:10.1016/s0165-5728(96)00117-8

Cited by 21 publications

(12 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this regard, we have previously achieved prevention of EAE in Wistar rats by i.p. administration of soluble MBP or whole BM prior to induction of the disease by sensitization with BM in CFA (Rivero et al, 1995(Rivero et al, , 1996. This study extends the preceding work and demonstrates that administration of myelin antigens in a nonimmunogenic form can also suppress CNS biochemical and histological alterations.…”

Section: Discussionsupporting

confidence: 84%

“…Coincidentally, previous results showed that in addition to reduction in clinical severity, i.p. treatment with myelin antigens prior to immunization determined a significant decrease in the in vitro proliferative responses of spleen lymphocytes to MBP (Rivero et al, 1995(Rivero et al, , 1996.…”

Section: Discussionmentioning

confidence: 99%

“…Using another experimental model of autoimmunity against rat male sex accessory glands induced by immunization with a chemically modified accessory gland saline extract (MRAG) in complete Freund's adjuvant (CFA), we have previously shown that a purified fraction of rat male accessory glands intraperitoneally administered in low doses and soluble form prevents the cellular and humoral autoimmune response when animals are subsequently challenged with MRAG in CFA (Ferro et al , 1985(Ferro et al , , 1990Rivero et al, 199 1). Application of a similar experimental model to EAE demonstrated inhibition of the clinical signs of the disease with a concurrent suppression of the proliferative response of mononuclear cells to MBP (Rivero et al, 1995(Rivero et al, , 1996.…”

Section: Introductionmentioning

confidence: 94%

See 2 more Smart Citations

Experimental autoimmune encephalomyelitis: Antigen-induced inhibition of biochemical and immunohistological alterations

et al. 1996

Self Cite

View full text Add to dashboard Cite

A comprehensive biochemical, immunological, and histological study was undertaken during suppression of experimental autoimmune encephalomyelitis (EAE) induced by antigen‐specific inhibition of the immune response. Pretreatment of Wistar rats by intraperitoneal administration of low doses of saline‐soluble bovine myelin or myelin basic protein (MBP) but not with ovalbumin suppresses the appearance of the clinical symptoms of EAE induced by sensitization with bovine myelin in complete Freund's adjuvant. Analysis of the central nervous system (CNS) of animals pretreated with MBP or whole myelin shows inhibition of the diminution of MBP and 2′,3′‐cyclic nucleotide 3′‐phosphohydrolase (CNPase) activity observed in the EAE animals or in rats pretreated with ovalbumin. With respect to the CNS lipid content, these suppressive treatments abolish the increase in esterified cholesterol and partially revert the diminution in the content of cerebrosides and total cholesterol characteristic of the acute stage of the disease. Concomitantly, meningeal and parenchymal infiltration with mononuclear cells and deposits of immunoglobulins in the infiltrated regions as well as in spinal cord motor neurons were reduced. Analysis of the humoral response to myelin antigens shows that all EAE as well as treated animals developed antibodies to MBP and other myelin proteins. However, a higher incidence and level of these antibodies was observed in nontreated EAE animals and MBP‐ and ovalbumin‐treated rats, while rats treated with total bovine myelin showed a highly reduced humoral response. The present results indicate that intraperitoneal treatment with soluble forms of myelin antigens, concomitant with the suppression of the clinical symptoms of the disease, markedly reduces the biochemical and histological alterations occurring in EAE animals and produces changes in the autoimmune humoral response. © 1996 Wiley‐Liss, Inc.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 94%

See 1 more Smart Citation

Experimental autoimmune encephalomyelitis: Antigen-induced inhibition of biochemical and immunohistological alterations

et al. 1996

Self Cite

View full text Add to dashboard Cite

show abstract

“…injections of MBP some 7–10 days prior to encephalitogenic challenge. Protected animals showed a higher incidence and level of IgG1 anti‐MBP antibodies than untreated animals 63 …”

Section: Treatment With Soluble Neuroantigenmentioning

confidence: 93%

“…Protected animals showed a higher incidence and level of IgG1 anti-MBP antibodies than untreated animals. 63 It has been known for a number of years that the dose of antigen can determine the type of immune response mounted; 64 that is, either humoral or cellular. The ability of high-dose systemic MBP to deviate the response in our model might be explained by the fact that the animals had been primed for an antibody response following high-dose infusion.…”

Section: Inhibition Of Eaementioning

confidence: 99%

Approaches to the treatment of central nervous system autoimmune disease using specific neuroantigen

Willenborg

Staykova

1998

Immunol Cell Biol

View full text Add to dashboard Cite

Summary The ultimate aim in the treatment of autoimmune disease is to restore self-tolerance to the autoantigen(s) in question. In lieu of this ideal result, the conversion of a destructive or pathogenic autoimmune response into one of benign autoimmunity would also be highly desirable. In either case the use of the antigenic epitope, which is the target of the destructive immune response, would ideally be employed so as to give speci®city to the protection without the need for long-term immunosuppression. This review describes a number of di erent approaches using various forms, doses, and routes of injection of speci®c neuroantigen to inhibit the di erent clinical varieties of autoimmune encephalomyelitis in a number of animal models; all done with the view to translating the ®ndings into the clinic for the treatment of multiple sclerosis. We conclude that any treatment strategy for multiple sclerosis (MS) must have a number of features: it must be clinically acceptable, speci®c, longlasting, require only short-term treatment, able to shut o ongoing disease, and have the potential to prevent or deal with epitope spreading. Few of the approaches we describe ful®ll all of these criteria. We suggest that investigations of new adjunctive agents to be used with a speci®c antigen be pursued, and that currently the use of chimeric proteins or DNA vaccination with or without the new adjunctives may hold the most hope for the future.

show abstract

Chronic Varied Stress Modulates Experimental Autoimmune Encephalomyelitis in Wistar Rats

Correa

Rodríguez-Galán

Rivero

et al. 1998

Brain, Behavior, and Immunity

View full text Add to dashboard Cite

Suppression of experimental autoimmune encephalomyelitis (EAE) by intraperitoneal administration of soluble myelin antigens in Wistar rats

Cited by 21 publications

References 33 publications

Experimental autoimmune encephalomyelitis: Antigen-induced inhibition of biochemical and immunohistological alterations

Experimental autoimmune encephalomyelitis: Antigen-induced inhibition of biochemical and immunohistological alterations

Approaches to the treatment of central nervous system autoimmune disease using specific neuroantigen

Chronic Varied Stress Modulates Experimental Autoimmune Encephalomyelitis in Wistar Rats

Contact Info

Product

Resources

About